Clinical Observation of Paclitaxel Combined with Lobaplatin by Interventional Embolization Chemothera-py for Cervical Cancer
10.6039/j.issn.1001-0408.2017.17.19
- VernacularTitle:紫杉醇联合洛铂经介入栓塞给药化疗宫颈癌的临床观察
- Author:
Jing LIU
;
Menghong YU
;
Congmin ZHANG
;
Xing LIU
;
Ying QIAN
;
Yibo CHEN
- Keywords:
Paclitaxel;
Lobaplatin;
Interventional embolization;
Cervical cancer;
T lymphocyte subset;
Safety
- From:
China Pharmacy
2017;28(17):2374-2377
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate chemotherapeutic efficacy and safety of Paclitaxel combined with lobaplatin by inter-ventional embolization for cervical cancer. METHODS:Totally 68 cases of cervical cancer patients selected from our hospital dur-ing May 2010-Mar. 2014 were divided into control group and observation group according to therapy plan,with 34 cases in each group. Control group was given Paclitaxel liposome for injection 175 mg/m2 added into 5% Glucose injection 250 mL,ivgtt+Loba-platin for injection 80 mg/m2 added into 5% Glucose injection 250 mL,ivgtt. Observation group was given Paclitaxel liposome for injection 175 mg/m2+Lobaplatin for injection 80 mg/m2+5% Glucose injection 10 mL via percutaneous catheter after selecting uter-ine artery and tumor vessel by arterial catheterization arteriography,gelfoam embolization. Both groups were treated in the first day of every treatment course,21 d as a treatment course,for 3 courses. Clinical efficacies were observed in 2 groups as well as the levels of T lymphocyte subsets(CD4+,CD8+,CD4+/CD8+)before and after treatment. The occurrence of ADR during treatment,lo-cal recurrence and metastasis after 2 years,and survival situation were recorded. RESULTS:The total response rate of observatio group(85.29%)was significantly higher than that of control group(61.76%),with statistical significance(P<0.05). Before treat-ment,there was no statistical significance in the levels of CD4+,CD8+ or CD4+/CD8+ between 2 groups (P>0.05). After treat-ment,CD4+and CD4+/CD8+of 2 groups were increased significantly,while CD8+was decreased significantly;above indexes of ob-servation group were improved significantly compared to control group,with statistical significance (P<0.05). The survival time of observation group [(22.58±0.61)months] was significantly longer than that of control group [(17.61±1.32)months],and 2-year survival rate(70.59%)was significantly higher than control group(47.06%),with statistical significance(P<0.05). There were no statistical significance in incidence of disease control,incidence of total ADR and incidence of local recurrence and metastasis between 2 groups (P>0.05). CONCLUSIONS:Paclitaxel combined with lobaplatin by interventional embolization show definite chemotherapeutic efficacy for cervical cancer,and can improve the levels of T lymphocyte subset with good safety.
